Andrés Gómez-De León, Emmanuel Bugarin-Estrada, Perla R Colunga-Pedraza, Julia E Colunga-Pedraza, Rosario Salazar-Riojas, Mayra Valdés-Galván, Yadith K López-García, Mariana López-Garza, César H Gutiérrez-Aguirre, Olga G Cantú-Rodríguez, Consuelo Mancías-Guerra, Oscar González-Llano, David Gómez-Almaguer
INTRODUCTION: The use of filgrastim biosimilars for healthy adult and pediatric donor mobilization in hematopoietic stem cell transplantation has been met with increased safety and efficacy concerns in contrast to generic small molecule drugs. In Mexico, several filgrastim-intended copies (FIC) have been available and marketed since 2001, while no clinical comparability studies to evaluate their use in this setting have been published and thus are not considered to be true biosimilars...
April 4, 2019: Journal of Clinical Apheresis